We are live on ! Find out more
HBIO icon

Harvard Bioscience

72 hedge funds and large institutions have $74.1M invested in Harvard Bioscience in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 24 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3% less funds holding

Funds holding: 7472 (-2)

8% less capital invested

Capital invested by funds: $80.6M → $74.1M (-$6.47M)

13% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 24

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

Holders
72
Holders Change
-2
Holders Change %
-2.7%
% of All Funds
2.09%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
21
Reduced
24
Closed
13
Calls
$150K
Puts
Net Calls
+$150K
Net Calls Change
-$7K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
76
Bank of America
North Carolina
-$293K -6,439 Closed
CS
77
Credit Suisse
Switzerland
-$260K -5,712 Closed
CSM
78
Central Square Management
Illinois
-$123K -2,698 Closed
CCA
79
Catalyst Capital Advisors
New York
-$105K -2,298 Closed
Barclays
80
Barclays
United Kingdom
-$82.5K -1,794 -100%
Susquehanna International Group
81
Susquehanna International Group
Pennsylvania
-$64K -1,413 Closed
GC
82
Guggenheim Capital
Illinois
-$57K -1,245 Closed
BNP Paribas Financial Markets
83
BNP Paribas Financial Markets
France
-$2.23K -49 Closed
TA
84
Teachers Advisors
New York
-$1K -29 Closed

HBIO Hedge Fund Activity: Q3 2014 in Review

72 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2014, worth a combined $74.1M — down 8% from $80.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of HBIO and 11 opened new positions — a net loss of 2 holders — while 24 trimmed existing stakes and 21 added.

The largest buyer was Acadian Asset Management, adding an estimated $1.85M. The largest seller was Northern Trust, cutting an estimated $963K.

  • 72 institutional investors held Harvard Bioscience (HBIO) as of Q3 2014, down from 74 in Q2 2014.
  • Funds reported $74.1M of Harvard Bioscience stock for Q3 2014, down 8% quarter-over-quarter.
  • 11 funds opened new Harvard Bioscience positions in Q3 2014 and 13 closed out, a net change of -2 holders.
  • The largest Harvard Bioscience buyer in Q3 2014 was Acadian Asset Management, an estimated $1.85M added.
  • The largest Harvard Bioscience seller in Q3 2014 was Northern Trust, an estimated $963K sold.

Based on aggregated 13F filings for Q3 2014.